These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 26308312)
1. Cyproheptadine Use in Children With Functional Gastrointestinal Disorders. Madani S; Cortes O; Thomas R J Pediatr Gastroenterol Nutr; 2016 Mar; 62(3):409-13. PubMed ID: 26308312 [TBL] [Abstract][Full Text] [Related]
2. [Rome III classification of functional gastrointestinal disorders in children with chronic abdominal pain]. Plocek A; Wasowska-Królikowska K; Toporowska-Kowalska E Med Wieku Rozwoj; 2010; 14(4):350-6. PubMed ID: 21462479 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of cyproheptadine for treating dyspeptic symptoms in children. Rodriguez L; Diaz J; Nurko S J Pediatr; 2013 Jul; 163(1):261-7. PubMed ID: 23419589 [TBL] [Abstract][Full Text] [Related]
4. Cyproheptadine: A Potentially Effective Treatment for Functional Gastrointestinal Disorders in Children. Krasaelap A; Madani S Pediatr Ann; 2017 Mar; 46(3):e120-e125. PubMed ID: 28287686 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions on early functional gastrointestinal disorders. Salvatore S; Barberi S; Borrelli O; Castellazzi A; Di Mauro D; Di Mauro G; Doria M; Francavilla R; Landi M; Martelli A; Miniello VL; Simeone G; Verduci E; Verga C; Zanetti MA; Staiano A; Ital J Pediatr; 2016 Jul; 42(1):68. PubMed ID: 27423188 [TBL] [Abstract][Full Text] [Related]
6. High prevalence of nausea in children with pain-associated functional gastrointestinal disorders: are Rome criteria applicable? Kovacic K; Williams S; Li BU; Chelimsky G; Miranda A J Pediatr Gastroenterol Nutr; 2013 Sep; 57(3):311-5. PubMed ID: 23591912 [TBL] [Abstract][Full Text] [Related]
8. Long-Term Study of Children With ROME III Functional Gastrointestinal Disorders Managed Symptomatically in a Biopsychosocial Model. Madani S; Parikh S; Madani RS; Krasaelap A Gastroenterology Res; 2017 Apr; 10(2):84-91. PubMed ID: 28496528 [TBL] [Abstract][Full Text] [Related]
9. Clinical Response of Rifaximin Treatment in Patients with Abdominal Bloating. Yoon K; Kim N; Lee JY; Oh DH; Seo AY; Yun CY; Yoon H; Shin CM; Park YS; Lee DH Korean J Gastroenterol; 2018 Sep; 72(3):121-127. PubMed ID: 30270593 [TBL] [Abstract][Full Text] [Related]
10. Increased prevalence of celiac disease among pediatric patients with irritable bowel syndrome: a 6-year prospective cohort study. Cristofori F; Fontana C; Magistà A; Capriati T; Indrio F; Castellaneta S; Cavallo L; Francavilla R JAMA Pediatr; 2014 Jun; 168(6):555-60. PubMed ID: 24756157 [TBL] [Abstract][Full Text] [Related]
11. Functional gastrointestinal disorders in eating disorder patients: altered distribution and predictors using ROME III compared to ROME II criteria. Wang X; Luscombe GM; Boyd C; Kellow J; Abraham S World J Gastroenterol; 2014 Nov; 20(43):16293-9. PubMed ID: 25473186 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of functional gastrointestinal disorders in school-aged children in El Salvador. Zablah R; Velasco-Benítez CA; Merlos I; Bonilla S; Saps M Rev Gastroenterol Mex; 2015; 80(3):186-91. PubMed ID: 26297182 [TBL] [Abstract][Full Text] [Related]
14. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial. Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995 [TBL] [Abstract][Full Text] [Related]
15. A retrospective review of cyproheptadine for feeding intolerance in children less than three years of age: effects and side effects. Merhar SL; Pentiuk SP; Mukkada VA; Meinzen-Derr J; Kaul A; Butler DR Acta Paediatr; 2016 Aug; 105(8):967-70. PubMed ID: 27194450 [TBL] [Abstract][Full Text] [Related]